1
                                  EXHIBIT 99.1

                                  PRESS RELEASE
   2
TUESDAY, SEPTEMBER 3, 8:23 AM EDT

LASERSCOPE COMPLETES ACQUISITION OF HERAEUS SURGICAL

MANAGEMENT FORESEES INCREASES IN REVENUE AND PROFITABILITY

SAN JOSE, Calif.--(BUSINESS WIRE)--Sept. 3, 1996-- Laserscope Inc. announced
today that it has completed its acquisition of Heraeus Surgical Inc.

"We expect the acquisition of Heraeus Surgical to have a very positive effect on
shareholder value while making Laserscope a stronger, more competitive company,"
said Robert V. McCormick, Laserscope president and CEO.

"With combined annual sales of more than $60 million Laserscope is now one of
the world's largest medical laser companies and a major force in the industry.

"In the short-term," continued McCormick, "we believe the company is
strategically positioned to benefit from ongoing growth in both the leg vein and
skin resurfacing markets.

"We have received more than 100 orders since the beginning of the year for our
new Aura Laser System, making substantial inroads into the growing vascular
lesion market which includes leg vein treatment.

"We will also begin to market aggressively the newly acquired Paragon(TM) CO2
Laser, capitalizing on the strategies employed in our successful roll out of the
Aura Laser.

"We believe the company's mid-term opportunities lie in continued development of
the operating room systems business of Heraeus Surgical," said McCormick,
"specifically its ceiling-mounted equipment management and centralized smoke
evacuation (CVAC) systems.

"Potential changes in the healthcare arena could create considerable market
opportunities for their patented CVAC systems which remove hazardous airborne
debris from the operating room.

"We believe longer-term opportunities for the company lie in new regulatory
approvals of photodynamic therapy (PDT), an innovative cancer treatment that
utilizes photosensitive drugs and laser light to selectively kill diseased
cells," said McCormick.

To improve profitability further, Laserscope also said it expects to
incrementally reduce operating expenses of the combined company such that, in 12
months, operating expenses should be more than $3 million lower than current
levels.

"We believe we are well underway in our process of turning Laserscope around,"
concluded McCormick. "We believe the outlook for Laserscope for the foreseeable
future is very encouraging indeed."
   3
The acquisition was approved by Laserscope shareholders at a special
shareholders meeting on Aug. 30, 1996. The transactions were also finalized on
Aug. 30, 1996 at which time Heraeus MED GmbH received 4,609,345 shares of
Laserscope common stock and a cash payment of $2 million from Laserscope in
exchange for all of the outstanding capital stock of Heraeus Surgical Inc.

Statements in this announcement about future results are preliminary and based
on partial information and management assumptions.

Except for the historical information presented, the matters discussed in this
news release are forward-looking statements that involve risks and
uncertainties, including the ability to integrate successfully Heraeus
Surgical's business with that of Laserscope and reduce the combined company's
expenses, the timely development and market acceptance of new and acquired
products, the impact of competitive products and pricing, the effect and timing
of relevant domestic and international regulatory approvals and other risks
detailed from time-to-time in the company's public disclosure filings with the
U.S. Securities and Exchange Commission (SEC).

Copies of the most recent Forms 10K and 10Q are available upon request from
Laserscope's Investor Relations Department.

                           CONTACT: Laserscope
                                    Richard Wood, 408/943-0636 (IR/Media)
                               Dennis LaLumandiere, 408/943-0636 (Financial)